Clindamycin Phosphate Injection, Solution
FDA Recall NDC 0338-3612
Latest: Class II · Status: Ongoing · Initiated Aug 06, 2026 · 2 enforcement reports
Active & Historical Enforcement Reports
The FDA has identified 2 recorded enforcement report(s) associated with Clindamycin Phosphate (NDC 0338-3612). A significant event, classified as Class II, was initiated on Aug 06, 2026 by Baxter Healthcare Company. The reported reason for this action was: "CGMP Deviations"
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
Reported Recall Events
Class II Ongoing
CGMP Deviations
Aug 06, 2026
Sep 09, 2026
N/A
Recall Profile & Regulatory Data
Event ID
99500
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Baxter Healthcare Corporation
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide; Puerto Rico; and Chile.
Product Description
Clindamycin Injection USP in 5% Dextrose, 600 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3612-50.
Batch or Lot Expiration Information
Lot# NC193764, Exp Date: 10/18/2027
Lot# NC195232, Exp Date: 11/25/2027.
Affected Packages Involved in this Recall
0338-3410-50Clindamycin Phosphate
0338-3410-24Clindamycin Phosphate
0338-3612-50Clindamycin Phosphate
0338-3612-24Clindamycin Phosphate
0338-3814-50Clindamycin Phosphate
0338-3814-24Clindamycin Phosphate
Class II Ongoing
CGMP Deviations
Aug 06, 2026
Sep 09, 2026
N/A
Recall Profile & Regulatory Data
Event ID
99500
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Baxter Healthcare Corporation
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide; Puerto Rico; and Chile.
Product Description
Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3814-50.
Batch or Lot Expiration Information
Lot# NC185424, Exp Date: 2/12/2027
Lot# NC185479, Exp Date: 2/13/2027
Lot# NC193948, Exp Date: 10/23/2027.
Affected Packages Involved in this Recall
0338-3410-50Clindamycin Phosphate
0338-3410-24Clindamycin Phosphate
0338-3612-50Clindamycin Phosphate
0338-3612-24Clindamycin Phosphate
0338-3814-50Clindamycin Phosphate
0338-3814-24Clindamycin Phosphate
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.
